RxDoctor Payments Data

Yeeck Sim, MD

Neurology · Tucson, AZNPI 1437595048

Payments from drug & device makers

$64,979in general payments, 2019–2025

Across 260 payments — averaging $249.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$61K
  • AbbVie$595
  • UCB, Inc.$476
  • Jazz Pharmaceuticals Inc.$317
  • Novartis$241
  • EMD Serono, Inc.$203
  • plus $2K from 36 others

What the payments were for

  • Speaking & faculty fees$30,15079%
  • Travel & lodging$2,3776%
  • Food & beverage$5,38014%
  • Education$3161%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$64,979 in reported general payments places this provider in the 75th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,520,514
Medicare patients
624
Services billed
47,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate163$253,322
FinteplaFenfluramine Hcl12$218,726
BotoxOnabotulinumtoxina139$179,201
ZonegranZonisamide25$158,572
VimpatLacosamide62$130,794
BriviactBrivaracetam72$129,718
Aimovig AutoinjectorErenumab-Aooe122$89,521
KeppraLevetiracetam20$88,122
UbrelvyUbrogepant67$80,815
Emgality PenGalcanezumab-Gnlm104$80,457
FycompaPerampanel54$68,430
TopamaxTopiramate25$67,520
Nurtec OdtRimegepant Sulfate39$56,459
TrileptalOxcarbazepine16$54,448
LamictalLamotrigine16$39,632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Fintepla, Vimpat, Briviact$476$479,237146 claims
AbbVieBotox, Ubrelvy, Qulipta$595$298,590225 claims
SK Life Science, Inc.Xcopri$61,140$253,322163 claims
Eisai Inc.Fycompa$131$68,43054 claims
PfizerNurtec Odt, Dilantin$75$63,47654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 neurology providers in Arizona.

Other neurology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →